Abstracts tagged "B cells"

Abstract Number: 646 • 2014 ACR/ARHP Annual Meeting
ONO-4059 – a Highly Potent and Dual Oral Inhibitor of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase: Improves Anti-Nuclear Antibodies–mediated SLE in Mice
Yuko Ariza¹, Toshio Yoshizawa¹, Yoshiko Ueda¹, Masayuki Murata¹ and Kazuhito Kawabata², ¹Exploratory Research Laboratories 1, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ²Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex and heterogeneous autoimmune disease associated with the over production of high affinity autoantibodies, mainly raised against nuclear…
Abstract Number: 1956 • 2014 ACR/ARHP Annual Meeting
Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Gerda Horst³, Abraham Rutgers², Annemieke M.H. Boots⁴ and Elisabeth Brouwer⁵, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Hanzeplein 1, UMCG, Groningen, Netherlands
Background/Purpose: The role of B cells in auto-immunity may extend beyond the production of auto-antibodies. B cells can influence T cell responses via antigen presentation…
Abstract Number: 1471 • 2014 ACR/ARHP Annual Meeting
TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins
Marie-Laure Golinski¹, Martine Hiron², Céline Derambure², Clément Guillou¹, Manuel Fréret², Olivier Boyer³, Olivier Vittecoq⁴ and Thierry Lequerré⁵, ¹Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, ³Immunology, INSERM U905, University of Rouen, Rouen, France, ⁴Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵1 Rue De Germont, Chu De Rouen, Rouen, France
Background/Purpose Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T cells play a key role in the RA pathophysiology. RasGRP is a…
Abstract Number: 605 • 2014 ACR/ARHP Annual Meeting
Decreased Frequencies of Circulating Follicular Helper T Cell Counterparts and Plasmablasts in Ankylosing Spondylitis Patients Naïve for TNF Blockers
M. Belén Bautista-Caro¹, Irene Arroyo-Villa¹, Concepcion Castillo-Gallego¹, Eugenio De Miguel², Diana Peiteado¹, Chamaida Plasencia-Rodriguez¹, Alejandro Villalba¹, Paloma Sanchez-Mateos³, Amaya Puig-Kröger⁴, Emilio Martín-Mola¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain, ³Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁴Laboratorio de Inmuno-Metabolismo, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
Background/Purpose: Follicular helper T cells (Tfh), localized in lymphoid organs, promote B cell differentiation and function. Circulating CD4 T cells expressing CXCR5, ICOS and/or PD-1…
Abstract Number: 2980 • 2014 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis of CD19+ B Cells in Primary Sjögren’s Syndrome
Gunnel Nordmark¹, Juliana Imgenberg-Kreuz², Jonas Carlsson Almlöf², Jessica Nordlund², Roald Omdal³, Katrine B. Norheim³, Maija-Leena Eloranta⁴, Lars Rönnblom⁴ and Johanna K. Sandling², ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁴Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose Increasing evidence suggests an epigenetic contribution to the pathogenesis of autoimmune diseases, including primary Sjögren’s Syndrome (pSS) (1). A genome-wide DNA methylation study in…
Abstract Number: 1952 • 2014 ACR/ARHP Annual Meeting
Elucidation of Molecular Mechanisms of Breg Induction in Autoimmune Diseases
Shun-ichiro Ota, Hiroaki Niiro, Naoko Ueki, Yuri Hirosaki, Hirofumi Tsuzuki, Kumiko Noda, Siamak Jabbarzadeh-Tabrizi, Atsushi Tanaka, Hiroki Mitoma, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroshi Tsukamoto and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose The advent of B-cell depletion therapy in autoimmune diseases identifies a novel B cell population, referred to as regulatory B cells (Bregs), that exerts…
Abstract Number: 986 • 2014 ACR/ARHP Annual Meeting
Integrated Comprehensive Analysis of Immune Cell Subsets and Serum Protein Profile Identifies the Role of Pre-Germinal Center B Cells in Sjogren’s Syndrome Pathogenesis
Yoshiaki Kassai¹, Katsuya Suzuki², Rimpei Morita³, Maiko Takiguchi¹, Rina Kurisu¹, Takahiro Miyazaki¹, Akihiko Yoshimura³ and Tsutomu Takeuchi², ¹Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Whole blood flow cytometric analysis and serum protein profiling were commonly utilized to characterize disease-specific alterations in a wide variety of autoimmune diseases. However,…
Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting
Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Svein Joar A. Johnsen¹, Einar Gudlaugsson², Ivar Skaland², Emiel Janssen², Malin V. Jonsson³, Lars Helgeland⁴, Ellen Berget⁵, Roland Jonsson⁶ and Roald Omdal¹, ¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ²Stavanger University Hospital, Stavanger, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵University of Bergen, Bergen, Norway, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…
Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting
Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Herbert Struemper¹, William Freimuth², Christi Kleoudis³, Thi-Sau Migone⁴, David Roth³ and William Stohl⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Human Genome Sciences, Inc., Rockville, MD, ³GlaxoSmithKline, King of Prussia, PA, ⁴Igenica, Burlingame, CA, ⁵Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…
Abstract Number: 563 • 2013 ACR/ARHP Annual Meeting
Hold The Rituximab: Neuropsychiatric Disease In Murine Lupus Is Not B-Cell Dependent
Jing Wen¹, Ariel Stock¹, Haowei Wang², Mark Shlomchik², Maria Gulinello¹ and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric disease is one of the earliest clinical manifestations in systemic lupus erythematosus (SLE). However, the mechanisms leading to neuropsychiatric SLE (NPSLE) are not…
Abstract Number: 2905 • 2013 ACR/ARHP Annual Meeting
Demethylation of ITGAL (CD11a) regulatory sequences in CD4+T lymphocytes of Systemic Sclerosis
Yaoyao Wang¹, Ye Shu², Qing Wang¹, Ming Zhao¹, Gongping Liang¹, Qianjin Lu¹ and Rong Xiao¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Hunan Children's Hospital, Changsha, China

Background/Purpose: Systemic sclerosis (SSc) is an autoimmune connective tissue disease epitomized numerous cellular and humoral immunological abnormalities. The immune system undoubtedly plays a pivotal…
Abstract Number: 1604 • 2013 ACR/ARHP Annual Meeting
Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod on renal and inflammation biomarkers in patients with SLE during the phase 2b clinical trial PEARL-SC (NCT01162681)…
Abstract Number: 568 • 2013 ACR/ARHP Annual Meeting
Pneumococcal Polysaccharide Vaccination Regulates T and B Lymphocyte Cytokine Responses and Decreases Kidney Stat1 Levels In MRL/Lpr Mice In Vivo
Victor Gazivoda¹, Shikha Mehta², Luhan Wang³, Julia Ash⁴, Kirk E. Sperber³ and Ioannis Tassiulas³, ¹Medicine, New York Medical College, Valhalla, NY, ²New York Medical College, Valhalla, NY, ³Medicine-Rheumatology, New York Medical College, Valhalla, NY, ⁴Rheumatology, New York Medical College, Valhalla, NY
Background/Purpose: Zwitterionic polysaccharides can activate CD4+ T cells after processing and presentation by antigen-presenting cells. The 23-valent capsular polysaccharide pneumococcal vaccine, PneumoVax, protects against invasive…
Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Alexis Boneparth^1,2, Ramalingam Bethunaickan³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Feinstein Institute for medical Research, Manhasset, NY, ³Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…
Abstract Number: 1402 • 2013 ACR/ARHP Annual Meeting
Regulatory B10 Cells Are Decreased In Patients With Rheumatoid Arthritis and Inversely Correlated With Disease Activity
Claire I. Daien^1,2, Sarah Gailhac³, Thibault Mura⁴, Bernard Combe⁵, Michael Hahne¹ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Regulatory IL-10 producing B cells (B10) have been shown to prevent and cure collagen-induced arthritis in mice. In human, very little is known about…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].